Gamma Vinyl GABA
Executive Summary
FDA's Peripheral and Central Nervous System Drugs Advisory Cmte. will review ongoing studies of Merrell-Dow's IND anticonvulsant at Oct. 18 meeting. FDA previously asked the cmte. to review animal data on the drug in May 1984. At that time, the cmte. recommended continued human testing and parallel animal toxicity studies. FDA says that Merrell-Dow has informed the agency that "interim sacrifices of monkeys have detected vacuoles." FDA is asking for another opinion from the advisory cmte. on the continuation of testing.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.